Interferon Alfa-2b

Intron A

View Post: ODAC Recommends Approval of Pegylated Interferon Alfa-2b for ...
13 Oct 2009
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for pegylated interferon alfa-2b (PegIntron) in the adjuvant treatment of patients with stage III ...
View Blog: Cancer Network - http://www.cancernetwork.com/

View Post: Orphan drug designation granted to TNFerade for pancreatic cancer ...
4 Nov 2009
INTRON A SOLN MULTIDOSE PENS. Neoplasms > Biological response modifiers. Interferon alfa-2b, recombinant; 18millionIU, 30million IU, 60million IU; per pen; for SC inj; contains m-cresol. ...
View Blog: Latest articles from MPR News - http://www.empr.com/

View Post: Pegylated Interferon Alfa-2b Reduces Quality of Life in Stage III ...
29 Jul 2009 by mjames
Although it improves recurrence-free survival, adjuvant (post-surgery) treatment with pegylated interferon alfa-2b adversely affects quality of life among patients with Stage III melanoma. These results were published in the Journal of ...
View Blog: CancerConsultants - http://www.cancerconsultants.com/

View Post: Hepatitis Journal Review October, 2009
28 Oct 2009
The mean doses used were the standard 180 mcg/week for pegylated interferon alfa-2a (Pegasys) or 1.5 mcg/kg/week for pegylated interferon alfa-2b (PegIntron). However, the mean dose of ribavirin was 800 mg/day, below the current ...
View Blog: HepCNews from the HCV Advocate - http://www.hcvadvocate.org/feeds/HepCNews.xml

View Post: FDA Advisory Committee Recommends Approval of Schering-Plough ...
5 Oct 2009
"Today's positive recommendation of pegylated interferon alfa-2b by the committee represents an important step toward a potential new option in the treatment of Stage III malignant melanoma, especially as the incidence of the disease ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

View Post: Pegylated interferon alfa-2b improves recurrence free survival but ...
15 May 2009
Data on survival from the phase III EORTC 18991 study of adjuvant therapy with pegylated interferon alfa-2b (IFN) versus observation in resected stage III melanoma were published in the Lancet in 2008. This reported that at 3.8 years ...
View Blog: NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/

View Post: Cancer Journal: Latest cancer research Bevacizumab (Avastin) in ...
4 Sep 2009
A similar prolongation in PFS was reported in the 90206 trial with a median PFS of 8.4 versus 4.9 months for the bevacizumab-containing combination and the single agent interferon alfa-2b arms, respectively. An improvement in overall ...
View Blog: ecancer news - http://www.ecancermedicalscience.com/

View Post: U.S. FDA Issues Complete Response Letter Regarding PEGINTRON(R ...
2 Nov 2009
(NYSE: SGP - News) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON� (pegylated interferon alfa-2b) for the ...
View Blog: Latest articles from PMD - http://www.pmdcentral.com/

View Post: Melanoma Clinical Trial: Cisplatin, Temozolomide, Abraxane, With ...
1 Sep 2009
You will receive interferon alfa-2b by injection into fatty tissue. - You will begin your IL-2 infusion. The infusion will begin after you receive cisplatin and will continue non-stop until Day 5. On Day 2 of each cycle: - You will take ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...